Weight loss clinical trials are currently paying participants anywhere from $50 per visit to more than $10,000 for a full study, with most obesity research studies compensating in the range of $200 to $1,500 depending on the trial phase, duration, and what’s being asked of you. A Phase II or Phase III obesity drug trial might pay $50 to $100 per clinic visit over several months, while intensive Phase I studies — where you’re often staying overnight at a research facility — typically pay $1,000 to $5,000 per study, with a median around $3,070. Some longer Phase III trials pay $2,000 to $7,000 total. If you’re someone who meets the eligibility criteria and can commit the time, these trials offer a legitimate way to get paid while contributing to medical research that could reshape how obesity is treated. The timing has never been better to look into these opportunities.
There are currently more than 31 active clinical trials recruiting weight loss participants across the United States, with the heaviest concentration in California, Texas, Florida, and North Carolina. The explosion in GLP-1 receptor agonist drugs — names like Wegovy, Zepbound, and newer pills still in development — has driven pharmaceutical investment to unprecedented levels. The GLP-1 weight loss drug market hit $13.84 billion in 2024 and is projected to reach $48.84 billion by 2030. That kind of money flowing into drug development means more trials, more recruiting, and more compensation for participants. This article covers how much specific trial types actually pay, what the eligibility requirements look like, which drugs are being studied right now, and how to find legitimate studies near you.
Table of Contents
- How Much Do Weight Loss Clinical Trials Actually Pay Participants?
- What Drugs Are Being Tested in Obesity Clinical Trials Right Now?
- Why Are There So Many Obesity Trials Recruiting Right Now?
- How to Find and Screen for Legitimate Weight Loss Studies
- What Are the Risks and Limitations of Participating?
- How Drug Pricing Changes Are Affecting Trial Availability
- What to Expect From Weight Loss Trials in 2026 and Beyond
- Conclusion
- Frequently Asked Questions
How Much Do Weight Loss Clinical Trials Actually Pay Participants?
Compensation in weight loss clinical trials varies widely, and the range you’ll encounter depends almost entirely on the trial phase and what’s required of you. At the lower end, Phase II through Phase IV outpatient studies — where you visit a clinic periodically for bloodwork, weigh-ins, and medication pickup — typically pay $50 to $100 per visit. If a trial involves 10 to 20 visits over six months, you’re looking at $500 to $2,000 total. Phase I trials, which test safety and dosing in smaller groups, tend to pay significantly more because they often require overnight stays, frequent monitoring, and stricter dietary controls. The median compensation for a Phase I study sits around $3,070, though some intensive inpatient trials exceed $10,000. Phase III trials represent a middle ground. These are large-scale efficacy studies that need hundreds or thousands of participants, and they often pay $2,000 to $7,000 for the full duration. The tradeoff is time — Phase III obesity trials can run from several months to several years.
Compensation isn’t structured as a lump sum in most cases. You’ll receive payment per visit or per completed milestone, which means dropping out early means earning less. It’s worth noting that compensation is designed to cover your time, travel expenses, and any inconvenience from study-related procedures. The investigational medication itself, along with medical evaluations conducted during the trial, come at no cost to you. One important distinction: compensation varies by sponsor and geography. A trial run by Eli Lilly or Novo Nordisk at a major academic medical center in a high-cost city may pay more per visit than the same trial conducted at a smaller clinic in a rural area. Some research sites advertise compensation up to $10,000 total for longer or more involved studies. Always ask about the full payment schedule during screening — not just the per-visit rate, but how many visits are expected and what happens to compensation if the trial ends early or you need to withdraw.
What Drugs Are Being Tested in Obesity Clinical Trials Right Now?
The current wave of obesity clinical trials is dominated by GLP-1 receptor agonists and their next-generation cousins, and the results coming out of recent studies help explain why pharmaceutical companies are investing so aggressively. The headline trial in recent months has been SURMOUNT-5, which pitted Eli Lilly’s tirzepatide (sold as Zepbound) directly against Novo Nordisk’s semaglutide (sold as Wegovy). Published in the New England Journal of Medicine, the results showed tirzepatide produced 20.2 percent body weight loss compared to 13.7 percent for semaglutide at 72 weeks. That’s a significant margin, and it has fueled a wave of new tirzepatide-related trials. UCLA, for example, is currently recruiting for the REMAIN-1 cohort, enrolling patients with a BMI of 30 to 45 for tirzepatide treatment targeting at least 15 percent body weight loss. Beyond the injectable drugs already on the market, several next-generation compounds are generating significant trial activity. Orforglipron, a daily oral GLP-1 pill being developed by Eli Lilly, showed promising safety and efficacy results in the ATTAIN-1 trial, with results published in the New England Journal of Medicine in September 2025.
The significance here is the pill format — if approved, it would eliminate the need for weekly injections, which remains a major barrier for many patients. Retatrutide, a triple-agonist injection, is further back in the pipeline but showing promise for cardiometabolic benefits that go beyond weight loss alone. Amgen also recently had its Phase 1 obesity asset freed from an FDA clinical hold and is back in active trials. However, participating in a trial for a newer, less-tested drug carries different considerations than joining a study for an established medication. Phase I and early Phase II trials for compounds like Amgen’s asset involve more uncertainty about side effects and dosing. You may be among the first humans to receive a particular dose. The medical monitoring is more intensive for exactly this reason, and the compensation tends to be higher to reflect the added commitment. If you’re risk-averse but still want to participate, look for Phase III or Phase IV trials of drugs that already have substantial safety data — tirzepatide and semaglutide trials, for instance, where the known side effect profile is well documented.
Why Are There So Many Obesity Trials Recruiting Right Now?
The sheer volume of weight loss clinical trials available in 2026 is directly tied to two converging forces: an obesity epidemic that continues to worsen and a pharmaceutical market that sees enormous revenue potential in treating it. According to CDC data from August 2021 through August 2023, 40.3 percent of U.S. adults are obese, and 9.4 percent have severe obesity — up from 7.7 percent just a decade earlier. Every single state in the country now has an obesity prevalence of 25 percent or higher. The Midwest leads at 35.9 percent, followed by the South at 34.5 percent. Significant racial and ethnic disparities persist, with obesity rates of 49.9 percent among Black adults, 45.6 percent among Hispanic adults, 41.4 percent among White adults, and 16.1 percent among Asian adults. On the commercial side, the numbers are staggering.
Novo Nordisk’s semaglutide franchise — Wegovy and Ozempic combined — is projected to reach approximately $36 billion in 2026 revenue. Eli Lilly’s Mounjaro and Zepbound together accounted for roughly $36.5 billion of Lilly’s approximately $65.2 billion in 2025 revenue. The broader GLP-1 weight loss drug market is growing at an annual rate of 18.54 percent. When pharmaceutical companies see this kind of revenue trajectory, they pour money into developing the next generation of treatments — and every new drug candidate means new clinical trials that need participants. This is good news for anyone interested in paid research participation. The combination of high disease prevalence, intense commercial competition, and a pipeline full of drug candidates means the demand for trial participants is outpacing supply in many regions. Research sites in California, Texas, Florida, and North Carolina are particularly active, but major recruiting institutions like Clinical Research Atlanta, Artemis Institute, and MedStar Health operate across multiple states. The practical implication is that eligibility criteria for some trials may be broader than you’d expect, and compensation may be trending upward as sponsors compete for participants.
How to Find and Screen for Legitimate Weight Loss Studies
Finding a legitimate weight loss clinical trial requires some diligence, because the space is cluttered with lead-generation websites that collect your personal information and sell it to research sites rather than connecting you directly with studies. The most reliable starting point is ClinicalTrials.gov, the federal database maintained by the National Institutes of Health. You can search by condition (obesity, weight loss, overweight), location, and study phase. The NIDDK — the National Institute of Diabetes and Digestive and Kidney Diseases — also maintains a curated list of obesity-related clinical trials. For a more user-friendly search experience, sites like FindPaidClinicalTrials.com aggregate paid opportunities and filter by compensation. When comparing trials, weigh the total compensation against the total time commitment rather than just looking at the per-visit payment.
A trial that pays $75 per visit over 24 visits across 12 months yields $1,800 — but that’s 24 half-days at a clinic, plus travel time and whatever dietary or activity logging the protocol requires. A shorter Phase I study that pays $3,000 for a two-week inpatient stay might be a better fit if you can take time off work, but it comes with more restrictions on your daily life during the study period. Neither option is inherently better; the right choice depends on your schedule, your tolerance for clinic visits, and whether you’re comfortable with earlier-stage experimental treatments. The screening process itself typically involves a phone pre-screen followed by an in-person visit where your BMI, medical history, current medications, and lab values are evaluated. Most obesity trials require a BMI of 30 or above, though some accept participants with a BMI of 27 or higher if they have weight-related health conditions like type 2 diabetes or hypertension. Be honest during screening — falsifying information to qualify for a trial puts your health at risk and can result in removal from the study without compensation. Major recruiting institutions like UCLA, UCSD, and UCSF run their own screening processes, while private research networks like Artemis Institute and MedStar Health often have dedicated enrollment coordinators who can walk you through what to expect.
What Are the Risks and Limitations of Participating?
Clinical trials are medical experiments, and no amount of compensation changes that fundamental reality. Every trial involves some degree of uncertainty, particularly around side effects. The GLP-1 class of drugs is associated with known side effects including nausea, vomiting, diarrhea, and in rarer cases, pancreatitis and gallbladder problems. Newer compounds in earlier trial phases may carry risks that aren’t yet fully characterized. You’ll receive detailed informed consent documents before enrolling, and it’s worth reading them thoroughly rather than skimming — they outline every known risk and the procedures in place to manage adverse events. One limitation that catches some participants off guard is the possibility of being assigned to a placebo group. Many obesity trials are randomized and double-blinded, meaning neither you nor the research team knows whether you’re receiving the active drug or a placebo. In a trial like SURMOUNT-5, which compared two active drugs, every participant received treatment.
But in placebo-controlled trials, you might spend months attending clinic visits, logging meals, and getting bloodwork done without receiving any active medication. You’ll still be compensated for your time, but if your primary motivation is access to a weight loss drug you can’t otherwise afford, this is a real possibility to factor in. There are also practical limitations to consider. Trial protocols often restrict other medications, supplements, and sometimes even dietary changes during the study period. If you’re already taking medications for diabetes, blood pressure, or mental health conditions, some trials will exclude you or require a washout period. Long-duration trials of several months to several years demand a sustained commitment — missing too many visits can result in removal from the study. And while compensation covers your time and travel, it typically doesn’t cover childcare, lost wages from time off work, or other indirect costs. Do the math on total burden before committing to a study that spans a year or more.
How Drug Pricing Changes Are Affecting Trial Availability
The economics of weight loss drugs are shifting rapidly in ways that directly affect the clinical trial landscape. Under the TrumpRx direct-to-consumer program, weight loss injections launched at $350 per month, with prices expected to fall to around $250 per month within two years. Novo Nordisk slashed U.S. GLP-1 prices by up to 70 percent, though analysts still project semaglutide revenue to hold steady or even grow in 2026 due to surging demand. These price cuts are expanding the potential patient population, which in turn drives more clinical research to differentiate products in an increasingly crowded market.
For prospective trial participants, this competitive pressure is largely positive. When multiple companies are racing to prove their drug is superior — whether through greater weight loss, fewer side effects, cardiovascular benefits, or a more convenient delivery method like a daily pill — they need more participants, faster. The Eli Lilly pipeline alone, with orforglipron and retatrutide joining tirzepatide, requires tens of thousands of trial participants across multiple studies. Amgen’s re-entry into the space after its clinical hold was lifted adds yet another sponsor competing for the same pool of eligible participants. The result is more studies, broader eligibility criteria, and in many cases, higher compensation to attract and retain enrollees.
What to Expect From Weight Loss Trials in 2026 and Beyond
The obesity clinical trial pipeline is only getting larger. With the GLP-1 market projected to grow from $13.84 billion in 2024 to $48.84 billion by 2030, the investment in new drug development — and the trials that come with it — will continue accelerating. The next frontier includes oral medications like orforglipron that could eliminate the injection barrier, triple-agonist therapies like retatrutide that target multiple metabolic pathways simultaneously, and combination approaches that pair weight loss drugs with treatments for related conditions like fatty liver disease and sleep apnea.
For people considering participation, the landscape favors you right now more than at any point in the past decade. The number of active trials is growing, geographic coverage is expanding beyond traditional research hubs, and compensation reflects the urgency sponsors feel to fill enrollment targets. If you’ve been on the fence, 2026 is a particularly strong year to explore your options — especially if you’re located in or willing to travel to states like California, Texas, Florida, or North Carolina where trial density is highest.
Conclusion
Weight loss clinical trials offer a real opportunity to earn $200 to $1,500 or more while contributing to research that could improve treatment options for the more than 40 percent of American adults living with obesity. Compensation varies significantly by trial phase — from $50 to $100 per visit for outpatient studies up to $5,000 or more for intensive Phase I inpatient research — so understanding what’s required of you before committing is essential. The current landscape, driven by blockbuster GLP-1 drugs and fierce competition among pharmaceutical companies, means there are more paid opportunities available now than at any point in recent memory.
Start by searching ClinicalTrials.gov or the NIDDK clinical trials page for obesity studies recruiting in your area. Check your BMI eligibility, review the time commitment and compensation structure carefully, and read the informed consent documents before signing anything. Be realistic about what participation involves — this is medical research, not a guaranteed weight loss program — and factor in the possibility of placebo assignment and the full scope of time you’ll invest. If the fit is right, a clinical trial can be a meaningful way to get compensated for your time while accessing cutting-edge treatments that aren’t yet available to the general public.
Frequently Asked Questions
Do I have to be a certain weight to qualify for a weight loss clinical trial?
Most obesity trials require a BMI of 30 or above, which is the clinical threshold for obesity. Some studies accept participants with a BMI of 27 or higher if they also have weight-related health conditions like type 2 diabetes, high blood pressure, or sleep apnea. The REMAIN-1 trial at UCLA, for example, is enrolling patients with a BMI between 30 and 45.
Will I definitely receive the weight loss drug if I join a trial?
Not necessarily. Many trials are placebo-controlled, meaning some participants receive an inactive treatment instead of the study drug. In randomized studies, you typically have a 50-50 or 2-to-1 chance of receiving the active medication. Head-to-head trials like SURMOUNT-5, which compared tirzepatide against semaglutide, give every participant an active drug but you won’t choose which one.
How long do most weight loss clinical trials last?
Trial duration ranges from several weeks to several years depending on the study design and phase. Phase I safety studies might last two to four weeks. Phase III efficacy trials for drugs like tirzepatide or orforglipron often run 52 to 72 weeks or longer. You’ll know the expected timeline before you enroll.
Is clinical trial compensation taxable?
Yes. Compensation from clinical trials is considered taxable income by the IRS. If you earn more than $600 from a single research site in a calendar year, you should expect to receive a 1099 form. Keep records of all payments received, as smaller amounts are still reportable even if no 1099 is issued.
Can I participate in a weight loss trial if I’m already taking medication?
It depends on the specific trial protocol. Some studies exclude participants taking certain medications — particularly other diabetes or weight loss drugs — while others may allow them or require a washout period before enrollment. Disclose all current medications during screening so the research team can determine your eligibility safely.
Are weight loss clinical trials safe?
All clinical trials approved by the FDA undergo ethical review by an Institutional Review Board and include safety monitoring throughout the study. That said, every trial involves some degree of risk, especially for earlier-phase studies testing newer compounds. Known side effects of GLP-1 drugs include nausea, vomiting, and diarrhea. Rarer risks like pancreatitis are monitored closely. You can withdraw from any trial at any time without penalty.
